Tianjin Tianyao Pharmaceuticals Co Ltd (600488.SS)
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|54||2017||Chairman of the Board, General Manager|
|39||2017||Chief Financial Officer, Director|
|35||2014||Chief Technology Officer, Executive Deputy General Manager, Director|
|45||2017||Deputy General Manager|
|45||2014||Secretary of the Board|
- BRIEF-Tianjin Tianyao Pharmaceuticals to pay cash dividend of 0.36 yuan per 10 shares (before tax) for 2017
- BRIEF-Tianjin Tianyao Pharmaceuticals says chairman resigns
- BRIEF-Tianjin Tianyao Pharmaceuticals to sell 3.4 pct stake in trust firm
- BRIEF-Tianjin Tianyao Pharmaceuticals signs two API technical development commission contracts worth 3 mln yuan
- BRIEF-Tianjin Tianyao Pharmaceuticals production area of API passes FDA CGMP